Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
It is standard treatment to take anti-platelet medication after cardiac catheterization and
stent placement to help prevent the formation of blood clots that may cause heart attack or
stroke. The most commonly used anti-platelet medicine is clopidogrel (Plavix®). However,
researchers have found that people vary in their response to clopidogrel, in part because of
differences in their genes. Prasugrel (Effient®)is another anti-platelet medication used to
prevent clots. The genetic differences that affect clopidogrel response do not affect
prasugrel response. Recently, the FDA added a warning to the label of clopidogrel to notify
doctors and patients with certain genetic differences may not get the full benefit from
clopidogrel. Despite this, genetic testing for these variations is not usually done in
standard medical practice. The purpose of this study is to see if patients with certain gene
differences have fewer major cardiac events after stent placement if they are given
anti-platelet therapy guided by their individual genetic type compared to standard
anti-platelet therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore